Showing results (1-10 of 36) with videos related to
Sort By:
Pageof 4
Cancer Treatment and Research|January 4, 2024
Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?Dario Trapani, Edoardo Crimini, José Sandoval, et al.Current Opinion in Oncology|August 28, 2020
Adjuvant treatment of early male breast cancerChiara Corti, Edoardo Crimini, Carmen Criscitiello, et al.Breast Cancer Research and Treatment|February 6, 2022
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?Stefania Morganti, Antonio Marra, Edoardo Crimini, et al.The Oncologist|September 4, 2023
Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' TargetabilityLiliana Ascione, Edoardo Crimini, Dario Trapani, et al.Cancer Treatment Reviews|May 28, 2021
Precision medicine in breast cancer: From clinical trials to clinical practiceEdoardo Crimini, Matteo Repetto, Philippe Aftimos, et al.Expert Opinion on Biological Therapy|November 26, 2020
Margetuximab for the treatment of HER2-positive metastatic breast cancerPaolo Tarantino, Stefania Morganti, Jacopo Uliano, et al.Journal of Personalized Medicine|December 29, 2022
PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-NegativeLiliana Ascione, Paola Zagami, Eleonora Nicolò, et al.Expert Review of Clinical Pharmacology|September 30, 2021
Selective FGFR/FGF pathway inhibitors: inhibition strategies, clinical activities, resistance mutations, and future directionsMatteo Repetto, Edoardo Crimini, Federica Giugliano, et al.Cancer Treatment and Research|January 4, 2024
Fast Mimicking Diets and Other Innovative Nutritional Interventions to Treat Patients with Breast CancerFederica Giugliano, Laura Boldrini, Jacopo Uliano, et al.Investigational New Drugs|May 25, 2022
The return of RET GateKeeper mutations? an in-silico exploratory analysis of potential resistance mechanisms to novel RET macrocyclic inhibitor TPX-0046Matteo Repetto, Edoardo Crimini, Liliana Ascione, et al.Pageof 4